


Corrigendum to A Case Report of Diabetic Ketoacidosis With Combined Use of a Sodium Glucose Transporter 2 Inhibitor and Hybrid Closed-Loop Insulin Delivery

Journal of Diabetes Science and Technology
2023, Vol. 17(6) 1739
© 2019 Diabetes Technology Society
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/1932296819888062
journals.sagepub.com/home/dst


Singh S, Rushakoff RJ, Neinstein AB. A Case Report of Diabetic Ketoacidosis With Combined Use of a Sodium Glucose Transporter 2 Inhibitor and Hybrid Closed-Loop Insulin Delivery. *J Diabetes Sci Technol.* 2019;13(3):605-606. doi: 10.1177/1932296819838875

The sentence appearing on page 1 of the article, which was originally published as:

“One year before this event, she was started on empagliflozin (300 mg/day)” stated an incorrect dosing for empagliflozin, the correct dosage should be:

One year before this event, she was started on empagliflozin (10 mg/day).